麻豆传媒

Urology >

Prostate Cancer

News, opinions and meeting coverage in urology.

SEER Data Errors: NCI Looks To Avoid Repeats

Results reassuring as SEER audit nears completion

ASCO: Chemo-ADT Combo Still Winning in Prostate Cancer

Yet another report of survival improvement with upfront docetaxel plus hormonal therapy.

Frankie the Dog Fetches - and Finds Thyroid Cancer?

Canine trained in cancer scent detection gives few false positives in early test.

Seeds Top EBRT as Boost Tx in Prostate Cancer

And other advances in prostate cancer care from the Genitourinary Cancers Symposium.

Medicare to Pay for More FDG-PET Scans

WASHINGTON -- Up to three scans using 18F-fluorodeoxyglucose-enhanced positron emission tomography technology can be covered by Medicare for oncology treatment planning, the Centers for Medicare and Medicaid Services said.

Zytiga Prolongs Prostate Cancer Survival

ORLANDO -- Survival improved and disease progression slowed in men with metastatic castration-resistant prostate cancer treated in first line with abiraterone acetate (Zytiga).

Steroids Reduce Benefits of Prostate Ca Tx

ORLANDO -- Men with castration-resistant prostate cancer had worse survival when treated with corticosteroids, regardless of their primary treatment, a post-hoc analysis of a randomized trial showed.

Early Radiation Boosts Prostate Cancer Survival

ORLANDO -- Immediate radiation therapy after radical prostatectomy led to a 50% increase in long-term biochemical progression-free survival for patients with locally advanced prostate cancer, according to a study reported here.

Doctors Say 45 Common Tests 'Overused'

Nine specialty groups have listed tests and treatments that are frequently overused, such as antibiotics for sinus attacks and CT scans for low back pain, in the first phase of a long-term project.

FDA Warns of High-Grade Prostate Ca Risk With BPH Drugs

WASHINGTON -- The FDA has issued a warning of an increased risk of high-grade prostate cancer with the 5-alpha reductase inhibitors finasteride (Proscar) and dutasteride (Avodart), currently approved to treat benign prostatic hypertrophy.

ASCO GU: Switch to Degarelix Slows PSA

ORLANDO -- PSA progression slowed significantly in prostate cancer patients switched to degarelix (Firmagon) after 12 months of leuprolide therapy, data from an open-label extension study showed.

ASCO GU: Rise in PSA Slowed by Pomegranate

ORLANDO -- Prostate cancer patients had a six-month gain in PSA doubling time when treated with pomegranate extract, according to data reported here.

ASCO GU: Long Learning Curve for Robotic Prostate Removal

ORLANDO -- Three experienced surgeons needed more than 1,600 cases to achieve acceptable outcomes with robotic-assisted laparoscopic prostatectomy, data from a retrospective chart review showed.

Low Testosterone May Affect Cancer Survivors

Male cancer survivors with low testosterone levels experience reduced energy and sexual function, and thus might benefit from hormone replacement therapy, a new study found.

Fish, Shellfish Associated with Advanced Prostate Protection

SAN FRANCISCO -- Omega-3 fatty acids, particularly those found in dark fish and shellfish, are associated with protection against aggressive prostate cancer, a case-control study showed.

Men Encouraged to Consider Medication to Prevent Prostate Cancer

ALEXANDRIA, Va. -- Millions of healthy men ages 55 and older should talk to their physicians about taking a 5-alpha reductase inhibitor such as finasteride (Proscar) or dutasteride (Avodart) to prevent prostate cancer, according to a guideline issued by two medical groups.

No Need for PSA Testing After Age 75

BALTIMORE -- PSA testing for prostate cancer can be safely discontinued at age 75 in men who have PSA values less than 3 ng/mL, data from a large cohort study suggest.

High-Grade Tertiary in Prostate Cancer Biopsy Signals Trouble

BOSTON -- The Gleason score of 7 for localized prostate cancer may be a moving prognostic target, according to investigators here.